Literature DB >> 31380115

Erratum to "Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects".

Ralf Uebelhack1, Udo Bongartz1, Stephanie Seibt2, Gordana Bothe2, Pee Win Chong3, Patricia De Costa4, Natalia Wszelaki3.   

Abstract

[This corrects the article DOI: 10.1155/2019/3412952.].

Entities:  

Year:  2019        PMID: 31380115      PMCID: PMC6657607          DOI: 10.1155/2019/6189724

Source DB:  PubMed          Journal:  J Obes        ISSN: 2090-0708


In the article titled “Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects” [1], there was an error in the legend of Figure 1 that occurred during the production stage, as the color of the placebo results/bars has been replaced by the colors of the high dose results/bars and vice versa.
Figure 1

Responder rate for subjects who lost ≥3% and ≥5% of initial body weight at v6. LD = low dose; HD = high dose. ap < 0.001 vs. placebo; bp=0.026 vs. placebo; cp=0.015 vs. low-dose group.

The correct version of Figure 1 should be as follows:
  1 in total

1.  Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects.

Authors:  Ralf Uebelhack; Udo Bongartz; Stephanie Seibt; Gordana Bothe; Pee Win Chong; Patricia De Costa; Natalia Wszelaki
Journal:  J Obes       Date:  2019-02-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.